Navigation Links
New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
Date:5/15/2008

>Colorectal cancer

-- Avastin: The first presentation of data from Avastin-based therapy with

or without cetuximab (a drug which attacks cancer differently to

Avastin) in patients with metastatic colorectal cancer will be shared.

-- Avastin: Impressive long-term overall survival data at two years,

involving some 4,000 patients treated with Avastin first-line in

combination with a variety of chemotherapy regimens will confirm the

pivotal role that Avastin is now playing in patients with advanced

colorectal cancer. The results of the studies are significant because

over 50 percent of people diagnosed with colorectal cancer currently

die of the disease and these data show that improvements in survival

are achievable. (1)

Roche will present nearly 300 abstracts and posters at ASCO that demonstrate advances in other major cancers, as well as the data already described above in breast and colorectal. With one of the most comprehensive oncology research and development pipelines in the industry, Roche is striving to deliver even more treatment options in the fight against cancer. For example, Avastin's clinical trial program includes 40,000 patients worldwide.

Key sessions at which Roche data will be presented include:

Breast cancer

Avastin AVADO study. Miles D, et al, Sunday 1 June 2008,

Abstract No. LBA1011, oral 8:30am - 8:45am, E

presentation Hall D1

ASCO press briefing Saturday 31 May

2008, 9:00am, Press

Centre

Herceptin HER2-positive metastatic breast Tuesday 3 June 2008,

cancer study. Minckwitz G Von, et 8:00am - 12:00pm,

al, Abstract No. 1025, Poster No.
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
3. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
4. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Roche responds to announcement of IDEAL hepatitis C trial results
11. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 2Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 3Solve Skin Conditions and Receive Hair Loss Treatment from Home with New Line of Medical Devices Called Dermaray 55653 1Solve Skin Conditions and Receive Hair Loss Treatment from Home with New Line of Medical Devices Called Dermaray 55653 2Solve Skin Conditions and Receive Hair Loss Treatment from Home with New Line of Medical Devices Called Dermaray 55653 3Professional Healthcare Is Approved for Medicare Licenses at Additional Offices in California and Utah 55649 1Professional Healthcare Is Approved for Medicare Licenses at Additional Offices in California and Utah 55649 2ColorAlchemy is Featured on HeartandHome Radio Show and Shares the Secret Color for Instant Calm and Clarity 55644 1ColorAlchemy is Featured on HeartandHome Radio Show and Shares the Secret Color for Instant Calm and Clarity 55644 2ColorAlchemy is Featured on HeartandHome Radio Show and Shares the Secret Color for Instant Calm and Clarity 55644 3ColorAlchemy is Featured on HeartandHome Radio Show and Shares the Secret Color for Instant Calm and Clarity 55644 4